Extensive in vitro and in vivo studies have unequivocally revealed the significant growth-inhibitory effects of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-0 and HR+/HER2-low breast cancer cell subtypes. This evidence concerns the gene CDK4 and breast carcinoma.